HomePharmacologyOther

Other

View Category

Other

Pulmonary Illness and E-Cigarettes: New Devices with New Diseases

We are seeing patients with similar clinical characteristics that shared the used of e-cigarettes. Even though we...
solaci -
Learn More
Other

ESC 2019 | EVOPACS: Evolocumab to Reduce Cholesterol in Acute Coronary Syndromes

Eight weeks of treatment with evolocumab added to a regimen of high-intensity statins in patients with acute...
solaci -
Learn More
Other

ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries

Exhaustive intervention carried out by healthcare non-medical healthcare professionals with the support of community members resulted in...
solaci -
Learn More
Other

ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups

Dapagliflozin (a sodium glucose co-transporter 2 inhibitor), when indicated concomitantly with standard therapy, reduces significantly the...
solaci -
Learn More
Other

ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.

The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in...
solaci -
Learn More
Other

Must Post MI Patients Use B Blockers for Life?

Long-term use of B blockers after myocardial infarction has been questioned for a while now; in fact,...
solaci -
Learn More
Other

Heart and Brain: Risk Factors, Atrial Fibrillation and Dementia

For decades, physiologists have known what cardiologists often forget: heart and brain communicate intensely in a healthy...
solaci -
Learn More
Other

Though Systolic BP Seems More Important, Diastolic BP Should Not Be Disregarded

Systolic hypertension is more often associated to cardiovascular events. However, diastolic blood pressure should not be disregarded,...
solaci -
Learn More